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DESCRIPTION
A 56-year-old woman with previous breast cancer underwent a muscle-sparing transverse
rectus abdominis myocutaneous flap to her left breast. She developed marked flap swelling
postoperatively and episodes of pyrexia.
A breast wound swab grew Escherichia coli and Acinetobacter baumannii. This strain
of Acinetobacter was multidrug resistant, including resistance to meropenem.
QUESTIONS
1. What is Acinetobacter and how common is Acinetobacter infection?
2. How dangerous is Acinetobacter infection?
3. How is it diagnosed?
4. What precautions do you need to take and how do you treat it?
DISCUSSION
Acinetobacter is a pleomorphic aerobic gram-negative bacillus, increasingly found in hos-
pitalized patients. Isolates from patients usually reflect colonization as opposed to infection.
However, when the organism is pathogenic, it can be multidrug resistant and therefore dif-
ficult to treat. Acinetobacter infections rarely occur outside of health care settings but may
occur in tropical environments, wars, and natural disasters. Its natural environment includes
water and soil. In the hospital setting, it is most commonly found on the intensive care unit
and burns units. In human populations, it colonizes the respiratory and gastrointestinal
tracts, skin, and wounds. Some strains can survive in iron-deficient and dry environments
for months, leading to the increased risk of fomite contamination.1 It is estimated to be
the cause of 2% to 10% of all gram-negative infections in intensive care units in both the
United States and Europe.2
Acinetobacter has low virulence but can cause infection in those who are immuno-
compromised, have chronic disease, have surgical wounds, or have prolonged hospital
admissions. Infections caused by Acinetobacter can include bacteremia, hospital-acquired
pneumonia,meningitis, and urinary tract infections.3 It can contaminate traumatic and surgi-
cal wounds, causing soft-tissue infection and osteomyelitis. Infections from Acinetobacter
baumannii are renowned for being difficult to treat due to its antimicrobial resistance.
This is in part due to its effectiveness in acquiring genetic material from other organ-
isms and therefore rapidly developing drug resistance.4 A number of strains incorporate
a polysaccharide capsule that may stop complement activation and protect against phago-
cytosis from macrophages.5 The species also form biofilms to adhere to environmental
surfaces.6
Diagnosis can be achieved through taking appropriate samples for culture such as
wound swabs or blood. In outbreaks, it is easy to culture Acinetobacter from monitors
and equipment around the colonized patient. It is therefore paramount to thoroughly clean
the ward and operating room the patient has been in. Microbiologically, it is nonmotile,
catalase-positive, and oxidase-negative. In standard cultures, it appears as broad, short,
gram-negative rods in rapid growth phase but a more coccobacillary shape in stationary
phase. They do not reduce nitrate or ferment glucose.7
Those proven to be colonized with Acinetobacter should be isolated and appropriate
infection control measure put in place. Supportive care includes removing or replacing
any lines, catheters or drains. Regular discussion with Microbiology needs to take place
to define colonization versus infection, as well as appropriate antibiotic regimens. An-
tibiotics used include meropenem, tigecycline, minocycline, colistin, amikacin, rifampin,
and polymyxin B. Combination therapy may be required. Most infections, until recently,
were sensitive to the carbapenems, but cases of resistance have been increasing. Multidrug-
resistant Acinetobacter is commonly susceptible to antiseptic and disinfectants. Reports of
failure to contain the bacteria are more likely due to staff not following correct cleaning
procedures than to do with disinfectant resistance. Control of the outbreak is more likely to
occur when the source is identified and eliminated. Hydrogen peroxide vapor can also be
used as an effective mode of decontamination.8
In conclusion, Acinetobacter baumannii can be found as a colonizing bacterium with
no adverse effects. However, it can be contaminated easily within a hospital or battlefield
environment, and when it becomes an infective organism, it may be difficult to treat,
as multidrug resistance is common. Those who are immunocompromised, have chronic
disease, have surgical wounds, or have prolonged hospital admissions are particularly
vulnerable. When a patient is proven to be colonized with Acinetobacter, the patient should
be isolated and appropriate infection control measure put in place to prevent colonization
or infection of other patients.
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